Increased prime edit rates in KCNQ2 and SCN1A via single nicking all-in-one plasmids.

CRISPR Developmental and epileptic encephalopathy EF-1alfa EIEE Gene editing Human-induced pluripotent stem cells KCNQ2 Monogenic diseases Prime editing SCN1A

Journal

BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720

Informations de publication

Date de publication:
13 Jul 2023
Historique:
received: 07 06 2022
accepted: 07 06 2023
medline: 17 7 2023
pubmed: 14 7 2023
entrez: 13 7 2023
Statut: epublish

Résumé

Prime editing (PE) is the most recent gene editing technology able to introduce targeted alterations to the genome, including single base pair changes, small insertions, and deletions. Several improvements to the PE machinery have been made in the past few years, and these have been tested in a range of model systems including immortalized cell lines, stem cells, and animal models. While double nicking RNA (dncRNA) PE systems PE3 and PE5 currently show the highest editing rates, they come with reduced accuracy as undesired indels or SNVs arise at edited loci. Here, we aimed to improve single ncRNA (sncRNA) systems PE2 and PE4max by generating novel all-in-one (pAIO) plasmids driven by an EF-1α promoter, which is especially suitable for human-induced pluripotent stem cell (hiPSC) models. pAIO-EF1α-PE2 and pAIO-EF1α-PE4max were used to edit the voltage gated potassium channel gene KCNQ2 and voltage gated sodium channel gene SCN1A. Two clinically relevant mutations were corrected using pAIO-EF1α-PE2 including the homozygous truncating SCN1A R612* variant in HEK293T cells and the heterozygous gain-of-function KCNQ2 R201C variant in patient-derived hiPSC. We show that sncRNA PE yielded detectable editing rates in hiPSC ranging between 6.4% and 9.8%, which was further increased to 41% after a GFP-based fluorescence-activated cell sorting (FACS) cell sorting step. Furthermore, we show that selecting the high GFP expressing population improved editing efficiencies up to 3.2-fold compared to the low GFP expressing population, demonstrating that not only delivery but also the number of copies of the PE enzyme and/or pegRNA per cell are important for efficient editing. Edit rates were not improved when an additional silent protospacer-adjacent motif (PAM)-removing alteration was introduced in hiPSC at the target locus. Finally, there were no genome-wide off-target effects using pAIO-EF1α-PE2 and no off-target editing activity near the edit locus highlighting the accuracy of snc prime editors. Taken together, our study shows an improved efficacy of EF-1α driven sncRNA pAIO-PE plasmids in hiPSC reaching high editing rates, especially after FACS sorting. Optimizing these sncRNA PE systems is of high value when considering future therapeutic in vivo use, where accuracy will be extremely important.

Sections du résumé

BACKGROUND BACKGROUND
Prime editing (PE) is the most recent gene editing technology able to introduce targeted alterations to the genome, including single base pair changes, small insertions, and deletions. Several improvements to the PE machinery have been made in the past few years, and these have been tested in a range of model systems including immortalized cell lines, stem cells, and animal models. While double nicking RNA (dncRNA) PE systems PE3 and PE5 currently show the highest editing rates, they come with reduced accuracy as undesired indels or SNVs arise at edited loci. Here, we aimed to improve single ncRNA (sncRNA) systems PE2 and PE4max by generating novel all-in-one (pAIO) plasmids driven by an EF-1α promoter, which is especially suitable for human-induced pluripotent stem cell (hiPSC) models.
RESULTS RESULTS
pAIO-EF1α-PE2 and pAIO-EF1α-PE4max were used to edit the voltage gated potassium channel gene KCNQ2 and voltage gated sodium channel gene SCN1A. Two clinically relevant mutations were corrected using pAIO-EF1α-PE2 including the homozygous truncating SCN1A R612* variant in HEK293T cells and the heterozygous gain-of-function KCNQ2 R201C variant in patient-derived hiPSC. We show that sncRNA PE yielded detectable editing rates in hiPSC ranging between 6.4% and 9.8%, which was further increased to 41% after a GFP-based fluorescence-activated cell sorting (FACS) cell sorting step. Furthermore, we show that selecting the high GFP expressing population improved editing efficiencies up to 3.2-fold compared to the low GFP expressing population, demonstrating that not only delivery but also the number of copies of the PE enzyme and/or pegRNA per cell are important for efficient editing. Edit rates were not improved when an additional silent protospacer-adjacent motif (PAM)-removing alteration was introduced in hiPSC at the target locus. Finally, there were no genome-wide off-target effects using pAIO-EF1α-PE2 and no off-target editing activity near the edit locus highlighting the accuracy of snc prime editors.
CONCLUSION CONCLUSIONS
Taken together, our study shows an improved efficacy of EF-1α driven sncRNA pAIO-PE plasmids in hiPSC reaching high editing rates, especially after FACS sorting. Optimizing these sncRNA PE systems is of high value when considering future therapeutic in vivo use, where accuracy will be extremely important.

Identifiants

pubmed: 37443005
doi: 10.1186/s12915-023-01646-7
pii: 10.1186/s12915-023-01646-7
pmc: PMC10347817
doi:

Substances chimiques

Peptide Elongation Factor 1 0
RNA, Small Untranslated 0
KCNQ2 protein, human 0
KCNQ2 Potassium Channel 0
SCN1A protein, human 0
NAV1.1 Voltage-Gated Sodium Channel 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

156

Subventions

Organisme : Vrienden WKZ
ID : 1616091 (MING)
Organisme : FWO-FKM
ID : 1861419N
Organisme : FWO-FKM
ID : G041821N
Organisme : FWO-SB
ID : 1S59221N
Organisme : European Joint Programme on Rare Disease JTC 2020
ID : TreatKCNQ

Informations de copyright

© 2023. The Author(s).

Références

Nat Biomed Eng. 2021 Feb;5(2):190-194
pubmed: 32989284
Cell. 2021 Oct 28;184(22):5635-5652.e29
pubmed: 34653350
Stem Cells Dev. 2007 Aug;16(4):537-45
pubmed: 17784828
Epilepsia. 2017 Mar;58(3):436-445
pubmed: 28139826
Nucleic Acids Res. 2021 Oct 11;49(18):10785-10795
pubmed: 34534334
Nucleic Acids Res. 2022 Jan 25;50(2):1187-1197
pubmed: 35018468
Sci Adv. 2021 Apr 30;7(18):
pubmed: 33931459
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Mol Ther. 2007 Sep;15(9):1630-9
pubmed: 17609656
Elife. 2022 Sep 07;11:
pubmed: 36069759
Nat Commun. 2020 Oct 23;11(1):5352
pubmed: 33097693
Stem Cells. 2002;20(2):139-45
pubmed: 11897870
Nat Biotechnol. 2011 Jun 07;29(6):488-91
pubmed: 21654665
Dev Med Child Neurol. 2018 Jun;60(6):566-573
pubmed: 29573403
Nature. 2019 Dec;576(7785):149-157
pubmed: 31634902
Genome Res. 2017 May;27(5):849-864
pubmed: 28396521
Nat Biotechnol. 2022 Mar;40(3):402-410
pubmed: 34608327
BMC Biol. 2023 Jul 13;21(1):156
pubmed: 37443005
Cell Stem Cell. 2011 Jan 7;8(1):106-18
pubmed: 21211785
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Stem Cells Dev. 2008 Apr;17(2):279-89
pubmed: 18447643
J Tissue Eng Regen Med. 2019 Mar;13(3):369-384
pubmed: 30550638
CRISPR J. 2022 Feb;5(1):109-122
pubmed: 35133877
Nat Biotechnol. 2011 Dec 18;30(1):61-8
pubmed: 22178994
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242

Auteurs

N Dirkx (N)

Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. nina.dirkx@uantwerpen.vib.be.
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. nina.dirkx@uantwerpen.vib.be.

Wout J Weuring (WJ)

Department of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands. woutweuring2@gmail.com.

E De Vriendt (E)

Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.

N Smal (N)

Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

J van de Vondervoort (J)

Department of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.

Ruben van 't Slot (R)

Department of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.

M Koetsier (M)

Department of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.

N Zonnekein (N)

Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Tim De Pooter (T)

Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.

S Weckhuysen (S)

Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium.
Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.

B P C Koeleman (BPC)

Department of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH